Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E F Smit

Showing results (141-150 of 185) with videos related to

Pageof 19
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 27, 2003
Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958)M E R O'Brien, T Splinter, E F Smit, et al.
Cancer Chemotherapy and Pharmacology|March 9, 2006
Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancerJ R Kroep, E F Smit, G Giaccone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2001
Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patientsM Klein, M J Taphoorn, J J Heimans, et al.
British Journal of Cancer|December 4, 2008
Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patientsM I Galleges Ruiz, K Floor, S M Steinberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 22, 2024
Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners FoundationS Peters, S Loi, F André, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 2012
Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patientsD E Ediebah, C Coens, J T Maringwa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 3, 2010
Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidityE C J Phernambucq, F O B Spoelstra, W F A R Verbakel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2011
Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III studyB Biesma, A N M Wymenga, A Vincent, et al.
Immuno-Oncology Technology|August 26, 2024
Integrated noninvasive diagnostics for prediction of survival in immunotherapyM Yeghaian, Z Bodalal, T M Tareco Bucho, et al.
British Journal of Cancer|April 19, 2014
Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trialD E Ediebah, C Coens, E Zikos, et al.
Pageof 19

Showing results (141-150 of 185) with videos related to

Sort By:
Pageof 19
European Journal of Cancer (Oxford, England : 1990)|June 27, 2003
Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958)M E R O'Brien, T Splinter, E F Smit, et al.
Cancer Chemotherapy and Pharmacology|March 9, 2006
Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancerJ R Kroep, E F Smit, G Giaccone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2001
Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patientsM Klein, M J Taphoorn, J J Heimans, et al.
British Journal of Cancer|December 4, 2008
Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patientsM I Galleges Ruiz, K Floor, S M Steinberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 22, 2024
Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners FoundationS Peters, S Loi, F André, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 2012
Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patientsD E Ediebah, C Coens, J T Maringwa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 3, 2010
Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidityE C J Phernambucq, F O B Spoelstra, W F A R Verbakel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2011
Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III studyB Biesma, A N M Wymenga, A Vincent, et al.
Immuno-Oncology Technology|August 26, 2024
Integrated noninvasive diagnostics for prediction of survival in immunotherapyM Yeghaian, Z Bodalal, T M Tareco Bucho, et al.
British Journal of Cancer|April 19, 2014
Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trialD E Ediebah, C Coens, E Zikos, et al.
Pageof 19